Daily non-political popular news in brief.

Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis

Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving Remicade (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50.

Read more »

Keywords: remicade, therapy, improve, productivity, patients, treated, chronic, plaque, psoriasis, patient, psoriasi

« Previous | Next »

Similar news on "Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis":

1. Survey indicates people with chronic moderate to severe plaque psoriasis may be undertreated
   02-02-2007 · EurekAlert!
   The National Psoriasis Foundation and Amgen today released data, which show that nearly 40 percent of patients with chronic moderate to severe psoriasis are not currently receiving any treatment. Further, more than half of moderate to severe patients on treatment are not being treated in accordance with AAD guidelines, which state that patients diagnosed with chronic moderate to severe plaque psoriasis are candidates for phototherapy or systemic therapy, including biologic agents.
   Similar news · Read more »
   
2. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
   02-02-2008 · EurekAlert!
   One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
   Similar news · Read more »
   
3. New findings show Enbrel significantly reduced levels of C-reactive protein
   02-01-2008 · EurekAlert!
   Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein, a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group. These results will be presented today at the American Academy of Dermatology Scientific Meeting in San Antonio, Texas.
   Similar news · Read more »
   
4. First placebo-controlled study of cognitive impairment due to chronic Lyme disease
   10-10-2007 · EurekAlert!
   Findings from the first placebo-controlled study of chronic cognitive impairment after treated Lyme disease demonstrate that patients report moderate cognitive impairment, physical dysfunction comparable to patients with congestive heart failure, and fatigue comparable to patients with multiple sclerosis. In the study, repeated intravenous antibiotic therapy was shown to be effective in treating cognitive dysfunction and the debilitating pain, fatigue and physical dysfunction associated with this disease.
   Similar news · Read more »
   
5. Pre-treatment blood test could guide lung cancer therapy
   06-05-2007 · EurekAlert!
   A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has developed a new pre-treatment blood test that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies (Iressa, Tarceva). The mass spectrometry-based test, described in the June 6 Journal of the National Cancer Institute, may allow physicians to select the most beneficial therapy for each lung cancer patient, a step forward in the era of personalized medicine.
   Similar news · Read more »
   
6. REMICADE-treated patients experienced substantial improvement in psoriasis in critical body regions
   02-01-2008 · EurekAlert!
   Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe psoriasis receiving REMICADE achieved a consistently high level of skin clearance in the head, trunk, lower and upper extremities as measured by the Psoriasis Area Severity Index. At week 10 of the analysis, 71 percent and 79 percent of patients receiving REMICADE 3 mg/kg or 5 mg/kg, respectively, achieved a at least a 75 percent improvement in psoriasis.
   Similar news · Read more »
   
7. Complete response with oblimersen combination improves survival of CLL patients
   12-09-2007 · EurekAlert!
   Relapsed chronic lymphocytic leukemia (CLL) patients who had a complete response to combination therapy that included the drug oblimersen survived significantly longer than patients treated with chemotherapy alone, a team led by researchers at the University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.
   Similar news · Read more »
   
8. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
   10-03-2007 · EurekAlert!
   The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index.
   Similar news · Read more »
   
9. New hope for patients with chronic lymphocytic leukemia
   12-04-2006 · EurekAlert!
   Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI). The results are published in the December 1 issue of the Journal of Clinical Oncology.
   Similar news · Read more »
   
10. Fosrenol does not further impact cognitive function deterioration in CKD Stage 5 patients
    10-18-2006 · EurekAlert!
    Newly published data from a large, two-year trial in the November Kidney International report on the effects of chronic kidney disease on cognitive function in CKD Stage 5 patients with hyperphosphatemia (high serum phosphorus levels in the blood), treated with phosphate binder therapy. This study is particularly relevant, as there is evidence that individuals with reduced renal function experience a significantly greater decline in cognitive function compared to those with normal renal function.
    Similar news · Read more »